GS-9876 (lanraplenib)
SYK-selective kinase inhibitor oral, completed Ph. I in HV from optimization of prior candidate ACS Med. Chem. Lett. Feb. 12, 2020 Gilead Sciences, Seattle, WA
Molecules of the Month - February 2020
Molecules of the Month
- LNP023
- LMB763 (nidufexor)
- ABBV-744
- AG-881
- FT-2102 (olutasidenib)
- GS-9876 (lanraplenib)
- "compound 25"
- "compound 25"-2
- WF-47-JS03
- BMS-986260
- GNF2133